Matthew W. Emmens

2012

In 2012, Matthew W. Emmens earned a total compensation of $6.9M as Former Chairman, President CEO at Vertex Pharmaceuticals, a 48% decrease compared to previous year.

Compensation breakdown

Option Awards$4,612,290
Salary$467,514
Stock Awards$1,786,558
Other$29,667
Total$6,896,029

Emmens received $4.6M in option awards, accounting for 67% of the total pay in 2012.

Emmens also received $467.5K in salary, $1.8M in stock awards and $29.7K in other compensation.

Rankings

In 2012, Matthew W. Emmens' compensation ranked 792nd out of 11,487 executives tracked by ExecPay. In other words, Emmens earned more than 93.1% of executives.

ClassificationRankingPercentile
All
792
out of 11,487
93rd
Division
Manufacturing
288
out of 4,252
93rd
Major group
Chemicals And Allied Products
63
out of 1,200
95th
Industry group
Drugs
34
out of 922
96th
Industry
Pharmaceutical Preparations
30
out of 697
96th
Source: SEC filing on April 4, 2013.

Emmens' colleagues

We found six more compensation records of executives who worked with Matthew W. Emmens at Vertex Pharmaceuticals in 2012.

2012

Jeffrey Leiden

Vertex Pharmaceuticals

Chief Executive Officer

2012

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2012

Peter Mueller

Vertex Pharmaceuticals

Chief Scientific Officer

2012

David Howton

Vertex Pharmaceuticals

Chief Legal Officer

2012

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2012

Kenneth Horton

Vertex Pharmaceuticals

Chief Legal Officer

In-depth

You may also like